Veracyte (FRA:12V) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:12V Veracyte Inc FRA:12V
75 GF Score
Price €50.16
GF Value €32.63
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Veracyte Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Veracyte's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:12V vs TWST, GRAL, RDNT: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Veracyte's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veracyte Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Veracyte's Margin of Safety % (DCF Earnings Based) falls into.


FRA:12V
75GF Score
Veracyte Inc FRA:12V
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Veracyte (FRA:12V) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of €50.16 is trading 53.7% above its estimated GF Value™ of €32.63. GuruFocus considers Veracyte to be Significantly Overvalued.

Key valuation signals for FRA:12V:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €32.63 vs. price of €50.16 (53.7% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the FRA:12V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Veracyte Business Description

Other Exchanges VCYT:USA12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score

Get the complete analysis for FRA:12V

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.16
Price
€32.63
GF Value